Phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy.

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2006
This article has no abstract
Epistemonikos ID: 9ecdd834702b6cb3c2034ef987b695ada4d1f7b6
First added on: Apr 16, 2025